Versions
- 2025-03-20 (3)
- 2023-06-29 (2)
- 2023-05-24 (1)
Keywords
anaphylaxis
epidemiology
food allergy
drug allergy
tryptase
epinephrine
Abstract
Objective: To characterize demographically and clinically the patients with anaphylaxis treated in a third level health institution in Medellin, Colombia.
Methods: A cross-sectional descriptive observational study was carried out, which includedpatients were diagnosed with anaphylaxis between 2009 and 2019. Information was retrieved from medical records through a collection instrument. Subsequently, a descriptive statistical analysis of proportions and measures of central tendency of the variables of interest was performed.
Results: 1820 records were reviewed and data from 253 patients were included. Among the reported comorbidities, drug allergy was the most prevalent (28%). The most frequent manifestations of anaphylaxis were cutaneous and respiratory. Most of the cases presented basal tryptase values ≤ 11.4 ng/mL (94,7%). Different etiological agents (food, drugs, insects and latex) were reported and their frequency varied according to age. Adrenaline, steroids, and antihistamines were the treatments of choice in 39,9%, 34,3%, and 39,9% of cases, respectively.
Conclusions: The characteristics of anaphylaxis in a medical center in Colombia coincide with those reported in Latin American. The treatment of anaphylaxis is not standardized, which makes it necessary to educate the health personnel and develop national guidelines.
References
1. Cardona V, Ansotegui IJ, Ebisawa M, et al. World allergy organization anaphylaxis guidance 2020. World Allergy Organ J. 2020;13(10):100472.
2. Website. Londoño JE, Raigosa M, Vasquez MC, Calvo V, Cardona R, Sánchez J. Evaluación de los conceptos diagnósticos y de manejo de la anafilaxia en médicos no alergólogos de Colombia [Internet]. Vol. 66, Revista Alergia México. 2019. p. 18–26. Disponible en: http://dx.doi.org/10.29262/ram.v66i1.524
3. Panesar SS, Javad S, de Silva D, et al. The epidemiology of anaphylaxis in Europe: a systematic review. Allergy. 2013;68(11):1353-1361. doi:10.1111/all.12272
4. Yu JE, Lin RY. The Epidemiology of Anaphylaxis. Clin Rev Allergy Immunol. 2018;54(3):366-374.
5. Cardona V, Álvarez-Perea A, Ansotegui-Zubeldia IJ, et al. [Clinical Practice Guide for Anaphylaxis in Latin America (Galaxia-Latam)]. Rev Alerg Mex. 2019;66 Suppl 2:1-39.
6. Simons FER, Ebisawa M, Sanchez-Borges M, et al. 2015 update of the evidence base: World Allergy Organization anaphylaxis guidelines. World Allergy Organization Journal. 2015;8:32. doi:10.1186/s40413-015-0080-1
7. Solé D, Ivancevich JC, Borges MS, et al. Anaphylaxis in Latin American children and adolescents: the Online Latin American Survey on Anaphylaxis (OLASA). Allergol Immunopathol . 2012;40(6):331-335.
8. Abunada T, Al-Nesf MA, Thalib L, et al. Anaphylaxis triggers in a large tertiary care hospital in Qatar: a retrospective study. World Allergy Organ J. 2018;11(1):20.
9. Website. Beltrán-Cárdenas CE, Granda-Restrepo DM, Franco-Aguilar A, Lopez-Teros V, Arvizu-Flores AA, Cárdenas-Torres FI, et al. Prevalence of Food-Hypersensitivity and Food-Dependent Anaphylaxis in Colombian Schoolchildren by Parent-Report. Medicina [Internet]. el 5 de febrero de 2021;57(2). Disponible en: http://dx.doi.org/10.3390/medicina57020146
10. Londoño JE, Raigosa M, Vasquez MC, Calvo V, Cardona R, Sánchez J. Evaluación de los conceptos diagnósticos y de manejo de la anafilaxia en médicos no alergólogos de Colombia. Revista Alergia México. 2019;66(1):18-26. doi:10.29262/ram.v66i1.524
11. Buka RJ, Knibb RC, Crossman RJ, et al. Anaphylaxis and Clinical Utility of Real-World Measurement of Acute Serum Tryptase in UK Emergency Departments. J Allergy Clin Immunol Pract. 2017;5(5):1280-1287.e2.
12. Jares EJ, Cardona Villa R, Sánchez-Borges M, et al. Drug-induced anaphylaxis, elicitors, risk factors, and management in Latin America. J Allergy Clin Immunol Pract. 2020;8(4):1403-1405.e1.
13. Maris I, Dölle-Bierke S, Renaudin JM, et al. Peanut-induced anaphylaxis in children and adolescents: Data from the European Anaphylaxis Registry. Allergy. 2021;76(5):1517-1527.
14. Webb LM, Lieberman P. Anaphylaxis: a review of 601 cases. Ann Allergy Asthma Immunol. 2006;97(1):39-43.
15. Jares EJ, Cardona Villa R, Sánchez-Borges M, et al. Drug-induced anaphylaxis, elicitors, risk factors, and management in Latin America. J Allergy Clin Immunol Pract. 2020;8(4):1403-1405.e1.
16. Turner PJ, Jerschow E, Umasunthar T, Lin R, Campbell DE, Boyle RJ. Fatal Anaphylaxis: Mortality Rate and Risk Factors. J Allergy Clin Immunol Pract. 2017;5(5):1169-1178.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright (c) 2023 Revista Alergia México